<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267304</url>
  </required_header>
  <id_info>
    <org_study_id>C13-02</org_study_id>
    <secondary_id>2013-003487-31</secondary_id>
    <nct_id>NCT02267304</nct_id>
  </id_info>
  <brief_title>Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic)</brief_title>
  <acronym>MBBAnalgesic</acronym>
  <official_title>Etude Comparative Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, de l'Action de la Morphine et de la Naloxone Dans un modèle Cognitif de Gestion Des Efforts Physiques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to examine the role of the opioïd system on the cognitive&#xD;
      parameters of motivation. They are embedded in a conceptual framework of motivation that&#xD;
      merges decision-making and reinforcement learning theories. Every action is conceived as path&#xD;
      from one state to another. The different states are associated to different values (positive&#xD;
      for rewards and negative for punishments), and the different actions to different costs&#xD;
      (risk, effort and delay). The tasks are designed such that the sensitivity to the state and&#xD;
      action parameters can be inferred by fitting computational models.The primary objective is to&#xD;
      characterize the effect of Morphine 0,05mg/kg and Naloxone 10mg on cost accumulation slope,&#xD;
      assessed in an effort management task, in which participants are asked to squeeze a hand grip&#xD;
      during 30 seconds at varying level of effort in order to win monetary payoff. Secondary&#xD;
      objectives are to characterize the effect of Morphine 0,05mg/kg and Naloxone 10mg on other&#xD;
      cognitive parameters of motivation (assessed with a motivational battery that includes&#xD;
      rating, choice and learning tasks).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2013</start_date>
  <completion_date type="Actual">August 30, 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cost Accumulation Slope (AU.)</measure>
    <time_frame>15 min after first placebo injection, 15 min after morphine (respectively naloxone) injection</time_frame>
    <description>The primary Outcome measure is the change in this parameter between the placebo condition and the morphine (respectively naloxone) condition.This parameter will be infered from the time spent in a effort period versus a rest period within trials of an effort managing task, for each subjects.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Morphine/placebo/naxolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naxolone/morphine/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo/naxolone/morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mL of sodium chloride (0,9%)</intervention_name>
    <arm_group_label>Morphine/placebo/naxolone</arm_group_label>
    <arm_group_label>Naxolone/morphine/placebo</arm_group_label>
    <arm_group_label>placebo/naxolone/morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine 0,05mg/kg</intervention_name>
    <arm_group_label>Morphine/placebo/naxolone</arm_group_label>
    <arm_group_label>Naxolone/morphine/placebo</arm_group_label>
    <arm_group_label>placebo/naxolone/morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone 10mg</intervention_name>
    <arm_group_label>Morphine/placebo/naxolone</arm_group_label>
    <arm_group_label>Naxolone/morphine/placebo</arm_group_label>
    <arm_group_label>placebo/naxolone/morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman, age ≥ 18 and &lt; 50&#xD;
&#xD;
          -  Weight between 50 kg and 90 kg.&#xD;
&#xD;
          -  No contraindication to effort&#xD;
&#xD;
          -  No evolutive pathology that could interfere with the current study signed consent&#xD;
&#xD;
          -  medical insurance (&quot;sécurité sociale&quot;)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 or &gt; 50&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Person under curatorship, or guardianship, or with civil rights deprivation&#xD;
&#xD;
          -  History of neurologic or psychiatric pathology&#xD;
&#xD;
          -  Chronic or actual consumption of alcohol, or psychotropic drugs&#xD;
&#xD;
          -  pregnancy, breastfeeding&#xD;
&#xD;
          -  Woman of childbearing potential without effective contraception&#xD;
&#xD;
          -  Liver failure&#xD;
&#xD;
          -  Severe Cardiovascular Disorders&#xD;
&#xD;
          -  Severe Cerebrovascular Discorders&#xD;
&#xD;
          -  Morphine (or Naloxone) hypersensitivity/addiction&#xD;
&#xD;
          -  Treatment contraindicated: morphine dérivatives, neuroleptics, barbiturate,&#xD;
             benzodiazepine, anxiolytics, hypnotics, antidepressant, antihistamine,&#xD;
             antihypertensives, beta blocker, baclofen, thalidomide&#xD;
&#xD;
          -  Enzyme inducers, (rifampicine, …)&#xD;
&#xD;
          -  Treatment that can interfere with the performance of the subject: beta2 adrenergic&#xD;
             agonists, analgesics, corticosteroïds, anti-inflammatory drugs, …&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean -Christophe Corvol, MCU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC Neurologie GH Pitié Salpêtrière</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC Neurologie GHPS</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 24, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

